Pasithea Therapeutics (KTTA) Competitors $0.71 -0.01 (-0.78%) As of 09:40 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock KTTA vs. GBIO, FGEN, FNCH, DARE, SLGL, MIRA, NAII, BCTX, RLMD, and DRRXShould you be buying Pasithea Therapeutics stock or one of its competitors? The main competitors of Pasithea Therapeutics include Generation Bio (GBIO), FibroGen (FGEN), Finch Therapeutics Group (FNCH), Dare Bioscience (DARE), Sol-Gel Technologies (SLGL), MIRA Pharmaceuticals (MIRA), Natural Alternatives International (NAII), Briacell Therap (BCTX), Relmada Therapeutics (RLMD), and DURECT (DRRX). These companies are all part of the "pharmaceutical products" industry. Pasithea Therapeutics vs. Its Competitors Generation Bio FibroGen Finch Therapeutics Group Dare Bioscience Sol-Gel Technologies MIRA Pharmaceuticals Natural Alternatives International Briacell Therap Relmada Therapeutics DURECT Generation Bio (NASDAQ:GBIO) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability. Do analysts rate GBIO or KTTA? Generation Bio presently has a consensus price target of $7.33, suggesting a potential upside of 1,965.73%. Given Generation Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Generation Bio is more favorable than Pasithea Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Generation Bio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Pasithea Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings and valuation, GBIO or KTTA? Pasithea Therapeutics has lower revenue, but higher earnings than Generation Bio. Generation Bio is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeneration Bio$19.89M1.20-$131.67M-$1.08-0.33Pasithea TherapeuticsN/AN/A-$13.90M-$10.60-0.07 Which has more risk and volatility, GBIO or KTTA? Generation Bio has a beta of 2.59, indicating that its stock price is 159% more volatile than the S&P 500. Comparatively, Pasithea Therapeutics has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Does the media prefer GBIO or KTTA? In the previous week, Generation Bio had 2 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 2 mentions for Generation Bio and 0 mentions for Pasithea Therapeutics. Generation Bio's average media sentiment score of 0.36 beat Pasithea Therapeutics' score of 0.00 indicating that Generation Bio is being referred to more favorably in the media. Company Overall Sentiment Generation Bio Neutral Pasithea Therapeutics Neutral Is GBIO or KTTA more profitable? Pasithea Therapeutics has a net margin of 0.00% compared to Generation Bio's net margin of -292.92%. Generation Bio's return on equity of -75.84% beat Pasithea Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Generation Bio-292.92% -75.84% -30.40% Pasithea Therapeutics N/A -88.14%-81.21% Do insiders and institutionals have more ownership in GBIO or KTTA? 95.2% of Generation Bio shares are held by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are held by institutional investors. 21.1% of Generation Bio shares are held by insiders. Comparatively, 16.3% of Pasithea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryGeneration Bio beats Pasithea Therapeutics on 12 of the 15 factors compared between the two stocks. Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KTTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KTTA vs. The Competition Export to ExcelMetricPasithea TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.29M$2.88B$5.50B$8.94BDividend YieldN/A2.45%5.25%4.04%P/E Ratio-0.0720.8026.9720.11Price / SalesN/A287.03426.02119.76Price / CashN/A41.1936.8257.86Price / Book0.077.487.985.56Net Income-$13.90M-$55.04M$3.16B$248.40M7 Day Performance-4.92%2.44%2.36%4.67%1 Month Performance-21.00%1.90%2.15%6.64%1 Year Performance-87.23%4.35%33.78%21.31% Pasithea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KTTAPasithea Therapeutics0.9796 of 5 stars$0.71-0.8%N/A-86.0%$5.29MN/A-0.073Gap UpGBIOGeneration Bio3.4307 of 5 stars$0.320.0%$7.33+2,191.7%-85.0%$21.46M$19.89M-0.30150News CoverageHigh Trading VolumeFGENFibroGen4.6939 of 5 stars$5.27-0.6%$250.00+4,643.8%-72.2%$21.42M$29.62M-2.11570Positive NewsFNCHFinch Therapeutics Group1.054 of 5 stars$13.20flatN/A+870.1%$21.20M$110K-1.50190DAREDare Bioscience1.5722 of 5 stars$2.37-0.8%$12.00+406.3%-22.3%$21.15M$10K-13.9430SLGLSol-Gel Technologies2.6268 of 5 stars$7.40-0.1%$40.00+440.9%-13.5%$20.61M$11.54M-1.5750MIRAMIRA Pharmaceuticals2.6545 of 5 stars$1.21flat$14.00+1,057.0%+106.3%$20.47MN/A-2.372NAIINatural Alternatives International0.873 of 5 stars$3.26-0.6%N/A-40.1%$20.27M$113.80M-2.35290Positive NewsGap UpBCTXBriacell Therap2.3313 of 5 stars$2.86-2.7%$32.00+1,018.9%-81.7%$19.92MN/A-0.348News CoverageRLMDRelmada Therapeutics4.5932 of 5 stars$0.62+2.6%$5.00+711.6%-80.9%$19.92MN/A-0.2510DRRXDURECT0.5376 of 5 stars$0.64+0.8%N/A-50.5%$19.72M$2.03M-4.2780Gap Down Related Companies and Tools Related Companies Generation Bio Alternatives FibroGen Alternatives Finch Therapeutics Group Alternatives Dare Bioscience Alternatives Sol-Gel Technologies Alternatives MIRA Pharmaceuticals Alternatives Natural Alternatives International Alternatives Briacell Therap Alternatives Relmada Therapeutics Alternatives DURECT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KTTA) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KTTA Stock Alerts